0000899243-20-020566.txt : 20200728 0000899243-20-020566.hdr.sgml : 20200728 20200728181139 ACCESSION NUMBER: 0000899243-20-020566 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200728 FILED AS OF DATE: 20200728 DATE AS OF CHANGE: 20200728 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hopfner Robert Lorne CENTRAL INDEX KEY: 0001551966 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 201055057 MAIL ADDRESS: STREET 1: C/O BAY CITY CAPITAL, LLC STREET 2: 750 BATTERY STREET, SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-28 1 0001693011 Inozyme Pharma, Inc. INZY 0001551966 Hopfner Robert Lorne C/O INOZYME PHARMA, INC. 321 SUMMER STREET, SUITE 400 BOSTON MA 02210 1 0 1 0 Common Stock 2020-07-28 4 C 0 1403654 A 1403654 I By Pivotal bioVenture Partners Fund I, L.P. Common Stock 2020-07-28 4 P 0 187500 16.00 A 1591154 I By Pivotal bioVenture Partners Fund I, L.P. Series A-2 Convertible Preferred Stock 2020-07-28 4 C 0 10489510 0.00 D Common Stock 1403654 0 I By Pivotal bioVenture Partners Fund I, L.P. On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd. Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Dr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein. /s/ Stephen Basso, as attorney-in-fact for Robert Hopfner 2020-07-28